Key Highlights
- Intelligent Bio Solutions completed its final clinical study, a Method Comparison Study across three US sites, clearing the last data requirement before a planned FDA 510(k) submission for its fingerprint-based drug screening device.
- The company completed a busy sequence of required studies within weeks, including usability testing, interference testing, and full remediation of Cybersecurity vulnerabilities, with submission targeted for the second half of 2026.
- Despite the regulatory progress, the company's most recent 10-Q carries a going-concern warning, with $6.86 million in cash against a nine-month operating burn of $8.74 million and an accumulated Deficit of $71.06 million.
Few micro-cap medical device companies have had a busier summer than Intelligent Bio Solutions Inc. (NASDAQ:INBS). Since late July the New York-based company has ticked off, one by one, the studies it needs before its first substantive US Food and Drug Administration filing.
The last landed on 11 August 2026, when INBS completed a multi-site Method Comparison Study, the final piece of clinical data for a planned 510(k) submission covering its Intelligent Fingerprinting Drug Screening System. The device screens for drug use from sweat collected on a fingertip, returns a result in under ten minutes and detects use within roughly the previous 16 to 24 hours.
The United States is, commercially, still largely closed to the product. INBS sells to employers in construction, manufacturing, transport and Mining outside the US and describes its customer base as numbering in the hundreds. Clearance would open the far larger American market, but the Balance Sheet leaves little room for delay.
What Happened
The study ran three weeks across three independent US clinical sites, enrolling 135 participants plus nine operators meant to represent typical workplace screening staff. Conducted with CenExel Clinical Research under ICH Good Clinical Practice guidelines, it measured sensitivity, specificity and accuracy for detecting codeine, an opiate. Samples are being independently checked by liquid chromatography-tandem mass spectrometry, the laboratory reference method used to identify and measure a sample's chemical components precisely.
It capped a busy fortnight. On 5 August INBS reported a usability study in which fifteen operators with no specialist laboratory background ran the system, and on 3 August an interference study in 75 healthy adults testing whether hand creams, alcohol, oils, dirt and water disturb the reading. Precision testing covering more than 1,600 tests was completed on 21 July.
On 23 July the company closed out the software and cybersecurity work regulators expect of connected devices, reporting full remediation of medium-risk vulnerabilities and all nineteen issues in its software bill of materials independently verified as resolved. Chief Executive Harry Simeonidis called the final study the milestone the entire programme had been building toward. Submission is targeted for the second half of calendar 2026.
Why It Matters
A 510(k) is the route by which a moderate-risk device is cleared for US sale by showing it is substantially equivalent to a product already marketed. Clearance would take INBS beyond the forensic-only applications it can address in the US today and into regulated workplace and clinical screening.
The commercial logic sits in the consumable: every reader placed with a customer pulls recurring cartridge sales behind it, and cartridges already made up 66% of third-quarter revenue. Production has also moved to Syrma Johari MedTech, a Partnership INBS says should cut annual production costs by more than 40% and lift gross Margin by roughly 20 percentage points.
The Numbers
For the fiscal third quarter ended 31 March 2026, INBS reported Revenue of $1.06 million, up 46% year on year. Cartridge sales rose 59% to $703,538 and other sales climbed 80% to $217,857, while reader sales fell 16%. Gross margin was 50.5%, against roughly 47% a year earlier.
Across the first nine months of fiscal 2026, revenue reached $3.07 million, up 39%, at a 49.3% gross margin, about eight percentage points better than the prior year.
Losses remain substantial: a quarterly net loss of $2.86 million on $3.65 million of operating expenses, a nine-month net loss of $8.52 million, an accumulated deficit of $71.06 million and $8.74 million of cash consumed by operations.
Cash and equivalents were $6.86 million at 31 March 2026, up from $1.02 million at 30 June 2025, funded by $14.67 million of net Capital raised, including a $10 million gross private Placement completed on 2 January 2026 with Ladenburg Thalmann as placement agent.
What It Means for the Company
The August announcements turn a long regulatory ambition into a filing that is now mostly analysis and assembly. Management called the cybersecurity work a meaningful de-risking event, and the open questions now are how the FDA responds and how the company funds the wait.
Commercially the base is real but small. A drug-testing rollout with Bouygues UK, part of the Bouygues Construction group, was announced in February and described by INBS as adding a significant new customer in the safety-critical sector, while second-quarter reader sales more than doubled year on year. The Equity itself has shrunk: a 1-for-10 reverse split in December 2025 left 2,391,846 shares outstanding by 12 May, and Market Capitalisation was near $7.3 million on 13 August 2026.
Risks Investors Should Watch
Funding is the most immediate risk. The March-quarter 10-Q carried a going-concern warning: management said existing cash might be insufficient to fund the operating plan for at least twelve months, raising substantial doubt about the company's ability to continue as a going concern. Against the nine-month burn, the March balance does not stretch far.
Dilution is the corollary. INBS registered an at-the-market Facility of up to roughly $3.97 million in March, and the January placement issued more than 2.29 million Series K-1 warrants, the same number of K-2 warrants and 2.19 million pre-funded warrants against a far smaller share count.
Regulatory risk has narrowed rather than vanished. Nothing has been filed yet, the FDA can request further data, and clearance is not assured. The initial indication covers a single analyte, codeine, so a first clearance would be a beachhead rather than a product line.
What Comes Next
Three near-term items dominate: the mass-spectrometry verification and data analysis from the Method Comparison Study; the 510(k) submission, guided to the second half of calendar 2026; and results for the fiscal year ended 30 June 2026, which had not been scheduled as at 14 August 2026.
Further out, a validation study begun in April targets results in under three minutes, aimed at a roadside testing market the company sizes at $1.17 billion.
Conclusion
Intelligent Bio Solutions has methodically checked off every study standing between it and an FDA submission, and completing that entire sequence within weeks shows real execution discipline for a company this size. Clearance would open the much larger US market beyond the forensic-only applications currently available domestically, and the recurring cartridge revenue model, already 66% of quarterly sales, gives the Business real Operating Leverage once readers are placed. But the going-concern warning in the same quarter's filing is a reminder that a 510(k) filing itself is not a clearance, and the company will likely need to fund the wait for an FDA response before any US commercial ramp begins.






Please wait processing your request...